Celldex drug meets goals in two late-stage trials
Celldex Therapeutics said its experimental drug for a skin disease met the main and secondary goals in two late-stage trials.
Celldex Therapeutics NASDAQ:CLDX said on Tuesday that its experimental drug for a skin disease met the main and secondary goals in two late-stage trials.